# Natera, Inc.  Share Price Target ‘$123.41’, now 10.6% Upside Potential

- Link: https://www.directorstalkinterviews.com/natera-inc.share-price-target-123.41-now-10.6-upside-potential/4121164704
- Published: 2024-07-12T13:47:43+01:00
- Author: Charlotte Edwards

**Natera, Inc.** which can be found using ticker (NTRA) now have 17 analysts in 
total covering the stock. The consensus rating is pointing to ‘buy’. The target 
price High/Low ranges between $160.00 and $37.00 with the average share target price
sitting at $123.41. (at the time of writing). Now with the previous closing price
of $111.58 this is indicating there is a potential upside of 10.6%. It’s also worth
noting that there is a 50 day moving average of $106.89 and the 200 moving average
now moves to $76.23. The market capitalization for the company is 13.61B. The stock
price for the company is currently $110.81 USD

 The potential market cap would be $15,050,533,916 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $10.31 and
a -17.14% return on assets.

Natera, Inc. is a diagnostics company that is focused on the development and commercialization
of molecular testing services, applying its technology in the fields of women’s 
health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology
combines its molecular assays, which reliably measure many informative regions across
the genome from samples as small as a single cell. The Company’s product offerings
include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening(
HCS), Spectrum Preimplantation Genetics, Anora Miscarriage Test (Anora) and Prospera.
The Company also offers Constellation, a cloud-based software platform that enables
laboratory customers to gain access through the cloud to the Company’s algorithms
and bioinformatics in order to validate and launch tests based on the Company’s 
technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as
in twin pregnancies, typically with a blood draw from the mother.

Share on: